Proactive Investors - Run By Investors For Investors

ECO Animal Health signs poultry vaccine development licencing deal with Ghent University

The vaccine is for Clostridium perfringens, a bacterium which normally inhabits the gastrointestinal system but when predisposing triggers are present, specific strains can cause necrotic enteritis with major consequences for bird health and growth
Poultry
In a note to clients, analysts at Peel Hunt said: “This continues the company's expansion of a vaccine development programme
A subsidiary of ECO Animal Health Group PLC (LON:EAH) has entered a worldwide exclusive development and licensing deal with Ghent University (UGA)  to further develop, register and commercialise a Clostridium perfringens vaccine for poultry.
 
The group said the deal allows it to further develop, register and commercialize a vaccine for poultry based on antigens co-developed by Prof. Filip Van Immerseel (Laboratory of Bacteriology, Faculty of Veterinary Medicine Ghent University) and Prof. Rick Titball (College of Life and Environmental Sciences, University of Exeter). Clostridium perfringens is a bacterium which normally inhabits the gastrointestinal system but when predisposing triggers are present, specific strains can cause necrotic enteritis with major consequences for bird health and growth.
 
 
Peter Lawrence, Non-Executive Chairman of ECO Animal Health commented: “Necrotic enteritis can result in a significant reduction in body weight and increase in feed conversion rate when compared with healthy broilers”.
 
In a note to clients, analysts at Peel Hunt said: “This continues the company's expansion of a vaccine development programme. The shares are trading on an ex-cash PE of 21.7x.”
 
Shares in the AIM-listed pharmaceutical firm were unmoved in early morning trading.
 
View full EAH profile View Profile

Eco Animal Health Group Plc Timeline

Related Articles

A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use